FCM
ALNY icon

Fourpath Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fourpath Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Buy
+691
New +$235K 0.03% 200
2025
Q4 		– Sell
-483
Closed -$220K – 229
2025
Q3 		$220K Buy
+483
New +$197K 0.03% 217

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fourpath Capital Management's ALNY Position: Q1 2026 in Review

Fourpath Capital Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 691 shares worth $229K. The stake represents 0.03% of the portfolio and ranks #200 among its holdings. This is a return to the name: Fourpath Capital Management previously reported a position in ALNY as recently as Q3 2025.

Fourpath Capital Management first reported a position in ALNY in Q3 2025 and has held it in 2 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Fourpath Capital Management held 691 shares of Alnylam Pharmaceuticals worth $229K as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Fourpath Capital Management position in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.03% of Fourpath Capital Management's portfolio in Q1 2026, its #200 holding.
  • Fourpath Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Fourpath Capital Management's 13F filing for Q1 2026, filed 1 May 2026.